Eli Lilly and Company does not intend to give up Trulicity (dulaglutide) market share to competitors’ glucagon-like peptide 1 (GLP-1) receptor agonists and it does not plan to shift patients from its blockbuster type 2 diabetes band to tirzepatide, if the dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) is approved next year. Instead, the company hopes to grow the overall GLP-1 market, in part by increasing prescriptions in the drug class for patients earlier in their treatment.
Lilly Aims For Earlier Treatment With Novel Diabetes Drugs
GLP-1/GIP Agonist Tirzepatide Leads Next-Gen Pipeline
Lilly outlined its tirzepatide-led pipeline of incretin agonists and highlighted its once-weekly basal insulin during a post-ADA event. The company hopes to grow the GLP-1 market overall rather than shift patients from Trulicity.
